Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?
Over
700 commonly used generic medicines were
recommended for suspension by the European Medic
